- Stocks
- Pharma & Healthcare
- Modern Diagnost
Modern Diagnost share price
NSE: MDRCPharma & HealthcareDiagnostics & Research
Modern Diagnost at a glance
With a market capitalisation of ₹81 Cr, it ranks 2781st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.
Its return on equity was 43.3% in FY25. In Q2 FY26, the quarter ended 30 Sep 2025, revenue was ₹21 Cr and net profit ₹0 Cr, on a standalone basis. Promoters held 72.85% of the company as of 31 Mar 2026.
Key numbers
- Market cap
- ₹81 CrRank 2781 on NSE
- Price to book
- 0×FY25
- ROE
- 43.3%FY25
- ROCE
- 44.8%FY25
- Debt to equity
- 1.07FY25
- Net profit margin
- 11.5%FY25
- Book value / share
- ₹18.84FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Modern Diagnost quarterly results
| Quarter | Q1 FY26 | Q2 FY26 |
|---|---|---|
| Revenue | ₹23 Cr | ₹21 Cr |
| Revenue YoY | — | — |
| Net profit | ₹3 Cr | ₹0 Cr |
| Net profit YoY | — | — |
| Net margin | 13.3% | 0.8% |
| EPS | ₹2.73 | ₹0.16 |
Modern Diagnost financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | ₹75 Cr | ₹60 Cr | ₹56 Cr | ₹67 Cr | ₹78 Cr |
| Operating profit | ₹13 Cr | ₹1 Cr | −₹6 Cr | ₹7 Cr | ₹13 Cr |
| Net profit | ₹10 Cr | −₹1 Cr | −₹6 Cr | ₹6 Cr | ₹9 Cr |
| EPS (₹) | ₹99.74 | −₹1.32 | −₹5.21 | ₹5.27 | ₹8.15 |
| Cash from operations | ₹15 Cr | ₹4 Cr | −₹0 Cr | ₹8 Cr | ₹14 Cr |
| Total debt | ₹13 Cr | ₹13 Cr | ₹6 Cr | ₹10 Cr | ₹8 Cr |
| Shareholders' equity | ₹5 Cr | ₹12 Cr | ₹6 Cr | ₹12 Cr | ₹21 Cr |
Modern Diagnost shareholding pattern
| Holder | 7 Jan 2026 | 31 Mar 2026 |
|---|---|---|
| Promoters | 72.85% | 72.85% |
| Foreign institutions | 1.07% | 0.03% |
| Domestic institutions | 11.80% | 15.48% |
| Non-institutions | 14.27% | 11.64% |
Modern Diagnost vs peers
The listed Pharma & Healthcare companies nearest to Modern Diagnost by market capitalisation.
Ask anything about Modern Diagnost
Pivot answers on the live chart with evidence you can check, and tests strategies against MDRC's own history. Try: “Why has MDRC moved over the last three months?” · “Backtest a 50-day moving-average crossover on MDRC over five years” · “Compare MDRC with FORTISMLR on margins and valuation”
Frequently asked questions about Modern Diagnost
What is the market cap of Modern Diagnost?
Modern Diagnost's market capitalisation is ₹81 Cr (₹81 Cr) at the 22 Oct 2026 close, ranking 2781st among the NSE companies Pivot tracks.
What is the ROE and ROCE of Modern Diagnost?
Return on equity was 43.3% in FY25 and return on capital employed was 44.8% in FY25 (standalone figures).
Is Modern Diagnost a debt-free company?
No. Modern Diagnost's debt-to-equity ratio was 1.07 in FY25, with total debt of ₹8 Cr.
What were Modern Diagnost's latest quarterly results?
For Q2 FY26 (quarter ended 30 Sep 2025), Modern Diagnost reported revenue of ₹21 Cr and net profit of ₹0 Cr.
What is the shareholding pattern of Modern Diagnost?
As of 31 Mar 2026: promoters 72.85%, foreign institutions 0.03%, domestic institutions 15.48%, non-institutions 11.64%.
Who are Modern Diagnost's competitors?
The listed Pharma & Healthcare companies closest to Modern Diagnost by market cap are Fortis Malar, Raaj Medisafe, KHFM HOSPITALIT, Amwill Health, Maestros Elect and Bharat Immuno.
Is Modern Diagnost a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Modern Diagnost's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on MDRC against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with M · all NSE stocks · this page as text